Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial
Status:
Unknown status
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
INTRODUCTION Polycystic ovary syndrome (PCOS) is one of the most common female endocrine
disorders (Fauser et al., 2011). It is a complex, heterogeneous disorder of uncertain
aetiology, but there is strong evidence that it can, to a large degree, be classified as a
genetic disease (Fauser et al., 2011). Genetic and environmental contributors to hormonal
disturbances combine with other factors, including obesity (Diamanti-Kandarakis et al.,
2006). Ovarian dysfunction and hypothalamic pituitary abnormalities contribute to the
etiology of PCOS (Doi et al., 2005).
It produces symptoms in approximately 5% to 10% of women of reproductive age (12-45 years
old). It is thought to be one of the leading causes of female subfertility (Goldenberg and
Glueck, 2008).
Its prevalence has increased with the use of different diagnostic criteria and has recently
been shown to be 18% (17.8 ± 2.8%) in the first community-based prevalence study based on
current Rotterdam diagnostic criteria (March et al., 2010).
AIM OF THE WORK The study will compare the luteal phase (early) administration of clomiphene
citrate to the conventional (late) administration of the same drug in the follicular phase as
regards ovarian response in PCOS.
Research Question What is the difference between administration of clomiphene citrate in the
luteal phase and the follicular phase for ovulation induction in women with PCOS? Research
Hypothesis Luteal phase administration of clomiphene citrate protocol gives better results
than conventional administration of clomiphene citrate in the follicular phase as regards
ovarian response in PCOS.